Recently, a pilot study of sirolimus, a mTOR inhibitor, in 18 CS patients has shown that this drug is well tolerated in these subjects, and its administration is associated with improvement of symptoms, skin lesions, cerebellar function, and decreased mTOR signaling [53]. This evidence concerns the gene MTOR and Cowden syndrome 1.